Dr Carmel McConville PhD

Dr Carmel McConville

Institute of Cancer and Genomic Sciences
Senior Lecturer

Contact details

Telephone
+44 (0)121 414 7286
Email
c.mcconville@bham.ac.uk
View my research portal
Address
Institute of Cancer and Genomic Sciences
University of Birmingham
Vincent Drive
Birmingham
B15 2TT
UK

Carmel McConville is a Senior Lecturer in the Institute of Cancer and Genomic Sciences. Her research interests are in the field of childhood cancer, particularly neuroblastoma and retinoblastoma.

Qualifications

  • PhD in Genetics, The Queen's University of Belfast, 1986
  • BSc (Hons) in Botany/Genetics, The Queen's University of Belfast, 1982

Biography

Carmel McConville undertook undergraduate and postgraduate study at the Queen's University of Belfast before joining the Cancer Research UK Institute for Cancer Studies at Birmingham University in 1985. There she carried out research into the genetics of the cancer predisposing disorder, ataxia telangiectasia. In 1995 Carmel took up a Senior Lecturer position at Birmingham Children's hospital to research childhood cancers, and has continued this work, based in the School of Cancer Sciences.

Teaching

Postgraduate supervision

Carmel supervises doctoral research students working in the field of childhood cancer.

Research

Research Themes

Cancer Genetics and Epigenetics.

Research Activity

Carmel's research is focused on understanding the molecular events leading to the development and progression of childhood solid tumours, particularly neuroblastoma and retinoblastoma. The approach is to integrate information from genome, epigenome, transcriptome and metabolome in order to define the molecular pathways which characterize tumour types and sub-types. Ultimately the aim is to translate this information into improved diagnosis and treatment for children with cancer.

Publications

Kohe S, Brundler MA, Jenkinson H, Parulekar M, Wilson M, Peet AC,  McConville CM, Metabolite profiling in retinoblastoma identifies novel clinicopathological subgroups. Br J Cancer, 2015. 113:  1216-24.

Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L,  De Santo C, Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Res, 2015. 75:  3043-53.

Pan X, Wilson M, McConville C, Arvanitis TN, Griffin JL, Kauppinen RA,  Peet AC, Increased unsaturation of lipids in cytoplasmic lipid droplets in DAOY cancer cells in response to cisplatin treatment. Metabolomics, 2013. 9:  722-9.

Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M, Peet AC,  McConville CM, Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer, 2013. 109:  512-25.

Pan X, Wilson M, McConville C, Brundler MA, Arvanitis TN, Shockcor JP, Griffin JL, Kauppinen RA,  Peet AC, The lipid composition of isolated cytoplasmic lipid droplets from a human cancer cell line, BE(2)M17. Mol Biosyst, 2012. 8:  1694-700.

Pan X, Wilson M, McConville C, Arvanitis TN, Kauppinen RA,  Peet AC, The size of cytoplasmic lipid droplets varies between tumour cell lines of the nervous system: a (1)H NMR spectroscopy study. MAGMA, 2012. 25:479-485.

Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RD, Kauppinen RA,  Peet AC, Lipid biomarkers of glioma cell growth arrest and cell death detected by (1) H magic angle spinning MRS. NMR Biomed, 2012. 25:1253-1262.

Pan X, Wilson M, Mirbahai L, McConville C, Arvanitis TN, Griffin JL, Kauppinen RA,  Peet AC, In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res, 2011. 10:  3493-500.

Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RD, Griffin JL, et al. (1)H magnetic resonance spectroscopy metabolites as biomarkers for cell cycle arrest and cell death in rat glioma cells. Int J Biochem Cell Biol. 2011. 43:990-1001.

Abbaszadeh F, Barker K, McConville C, Scott R, Rahman N. A new familial cancer syndrome including predisposition to Wilms tumor and neuroblastoma. Familial Cancer. 2010;9(3):425-30. 

Wilson M, Davies N, Brundler M-A, McConville C, Grundy R, Peet A. High resolution magic angle spinning 1H-NMR of childhood brain and nervous system tumours. Molec Cancer. 2009;8:6:doi:10.1186/476-4598-8-6. 

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner J, Attiyeh E, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature Genetics. 2009;41:718-23. 

Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, et al. Stratification of paediatric ALL by in vitro cellular responses to DNA double strand breaks provides insight into the molecular mechnanisms underlying clinical response. Blood. 2008;113:117-26. 

Maris J, Mosse Y, Bradfield J, Hou C, Monni S, Scott R, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. New Eng J Med. 2008;358:2585-93. 

Peet A, McConville C, Wilson M, Levine B, Reed M, Dyer S, et al. 1H Magnetic resonance spectroscopy identifies specific metabolite profiles associated with MYCN amplified and non-amplified tumour subtypes of neuroblastoma cell lines. NMR in Biomedicine. 2007;20:692-700. 

McConville C, Reid S, Baskcomb L, Douglas J, Rahman N. PHOX2B analysis in non-syndromic neuroblastoma cases reveals novel mutations. Am J Med Genet. 2006;140A:1297-301.

View all publications in research portal